The finding of high HRD score in uterine or ovarian carcinosarcoma is not unexpected as high HRD score is known to occur in a significant subset of TP53-mutated high-grade endometrial carcinoma/carcinosarcoma and in high-grade tubo-ovarian serous carcinoma/carcinosarcoma [40,41], with PARP inhibitor therapy being utilized clinically for the latter. This evidence concerns the gene TP53 and endometrial carcinoma.